Prostate Cancer: Surgery or Radiation Therapy? (2026 Guide)

For prostate cancer, there isn't one treatment that's simply "better" between surgery and radiation therapy — the standard approach is to choose the option that "fits" the individual, based on the risk group determined by PSA level, Gleason grade group, and stage, along with the patient's own condition.

Key Summary

• For intermediate-risk disease, both radical prostatectomy and radiation therapy are standard treatments, and the choice is often made based on differences in the nature of side effects rather than differences in outcomes.
• For low-risk disease, active surveillance — monitoring at set intervals without treatment — is included among the standard options.
• Korea's 5-year relative survival rate for prostate cancer is 96.9%, based on National Cancer Registry statistics for 2019–2023, and is not the result of any specific hospital (for reference, the U.S. rate based on SEER 2016–2022 is 98.2%).
• For high-risk or locally advanced disease, standard approaches include adding radiation after surgery, or combining radiation therapy with several years of hormone therapy.
• Robotic surgery is known to be favorable for nerve preservation, while radiation and particle therapy are reported to show changes in sexual function that tend to appear later and more gradually — though individual variation is substantial.

How Is the Choice Made Between Surgery and Radiation?

• Treatment decisions aren't based on stage alone — they combine PSA level, Gleason score (grade groups 1–5), and stage into a risk group, together with age, life expectancy, and coexisting conditions.
• Low-risk disease is confined to a small area within the prostate, with low PSA and the lowest grade group; in this case active surveillance is possible, and since the burden of incontinence or sexual side effects from treatment may outweigh the benefit, this approach is used.
• Intermediate-risk disease has both surgery and radiation as standard options, so the choice often comes down to comparing the nature of side effects (incontinence vs. changes in urination/bowel function); if radiation is chosen, a short course of hormone therapy may be combined with it.
• For high-risk or locally advanced disease, pelvic lymph nodes are removed along with the prostate during surgery, with radiation added depending on results; if radiation is chosen, combining it with several years of hormone therapy is part of the standard approach.

What Is the Treatment Sequence?

• Step 1: If abnormalities are found on PSA blood testing and digital rectal exam, a prostate MRI is performed first.
• Step 2: If a suspicious area is seen on MRI, an MRI-fusion biopsy targeting that specific area confirms the Gleason score and grade group.
• Step 3: MRI is used to check for invasion of the prostate capsule, and if the risk group is high, a bone scan or PSMA PET is used to check for metastasis and classify the risk group.
• Step 4: Based on the risk group, a suitable treatment is planned from among active surveillance, robotic surgery, IMRT/SBRT, or carbon-ion (heavy particle) therapy.
• Step 5: After treatment, follow-up is centered on PSA testing at set intervals — for surgery patients, checking whether PSA drops to an essentially undetectable level, and for radiation patients, checking whether it gradually settles at its lowest point (nadir).

How Do Side Effects and Recovery Time Differ?

• Robotic surgery typically requires a 5–7 day hospital stay. After the catheter is removed, nearly all patients experience some degree of incontinence at first, but most recover over several months with pelvic floor exercises. Erectile function depends on the degree of nerve preservation, and ejaculation is no longer possible once the prostate is removed.
• Radiation therapy and particle therapy commonly cause frequent or painful urination and changes in bowel habits during the treatment period; these usually settle within a few weeks after treatment ends, though in rare cases late bladder or bowel reactions can appear months to years later.
• Skin reactions from radiation therapy typically begin around 2 weeks into treatment, and moist desquamation (weeping skin breakdown) can occur around weeks 4–6, so using mild soap for cleansing, applying moisturizer, and avoiding direct sunlight are recommended.
• When hormone therapy is combined with treatment, hot flashes, reduced libido, fatigue, and decreased bone density can occur, so exercise and bone density testing should also be managed alongside treatment.

FAQ — Which Is Better, Surgery or Radiation Therapy?

There isn't a 'better' option — there's a 'right fit' for each person. The decision is based on age, risk group, priorities regarding incontinence versus sexual function, urinary status, and history of prior surgery or radiation. It's common practice for a written opinion to lay out both options side by side so the pros and cons can be compared.

FAQ — Does Carbon-Ion (Heavy Particle) Therapy Preserve Sexual Function?

Carbon-ion therapy is a type of radiation therapy that accelerates carbon ions and concentrates them on the tumor site; in Korea, it has been available since 2023. Radiation-based treatments are known to tend toward later and more gradual changes in sexual function compared to surgery, but individual variation is substantial, and the effect depends on whether hormone therapy is combined, so this is not something that can be assured for every patient.

Sources and Notes

• This article was written based on National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea), SEER 2016–2022, the National Cancer Information Center, and NCCN patient-level guideline information on prostate cancer, radiation therapy, carbon-ion therapy, and post-radiation care.
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.